CDKN2A and melanoma: In addition, other cancers have been observed in carriers, although actionable guidelines for increased surveillance for these cancers are not available at this time (18, 19).The penetrance rate for melanoma in individuals with CDKN2A PVs is estimated at 58-92% by age 80 (13, 20, 21).